Kazia Therapeutics delays annual report to complete internal control review
KZIA•Kazia Therapeutics delayed its Form 20-F for the year ended June 30, 2026, past the November 2 deadline and expects to file within 15 calendar days. The company also expects its net loss to widen from fiscal 2025.
1. Filing delay
Kazia Therapeutics delayed its annual report after becoming an accelerated filer, which triggered first-time Sarbanes-Oxley Section 404(b) requirements and added time for year-end reporting and internal-control assessments. It expects the net loss to widen from fiscal 2025, primarily because of higher operating expenses and non-cash fair value movements on financial liabilities.
